Key Takeaways From Biogen Analyst Ratings
Portfolio Pulse from Benzinga Insights
Biogen (NASDAQ:BIIB) received mixed analyst ratings, with 17 analysts providing a range of bullish to bearish perspectives. The average 12-month price target is $275.65, down from $285.18. Recent analyst actions include both maintaining and lowering ratings and price targets. Biogen's financial performance shows strong profitability and effective cost management, with a net margin of 23.68% and a debt-to-equity ratio of 0.42.
September 04, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's stock is under scrutiny with mixed analyst ratings. The average price target has decreased to $275.65, indicating a cautious outlook. Despite this, Biogen's financial metrics like net margin and debt management remain strong.
The mixed analyst ratings and lowered average price target suggest a cautious outlook for Biogen's stock in the short term. However, the company's strong financial performance, including a high net margin and low debt-to-equity ratio, provides a solid foundation, balancing the negative sentiment from analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100